The protective effects of exercise and phosphoinositide 3-kinase (p110α) in the failing heart

Clinical Science

Volumn 116, Issue 5, 2009, Pages 365-375

  Owen, Kate L ^a,b   Pretorius, Lynette ^a,c   McMullen, Julie R ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Cardiac hypertrophy; Exercise; Heart failure; Phosphoinositide 3 kinase (PI3K); Protection

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P110 ALPHA; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SOMATOMEDIN C; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; 1 PHOSPHATIDYLINOSITOL 3 KINASE P110 SUBUNIT, HUMAN; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, HUMAN; CARDIOTONIC AGENT;

AEROBIC EXERCISE; APOPTOSIS; CATALYSIS; CONGESTIVE CARDIOMYOPATHY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXERCISE; FATTY ACID OXIDATION; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HORMONE RELEASE; HUMAN; NONHUMAN; PATIENT SAFETY; PHARMACOLOGICAL BLOCKING; PHYSICAL TOLERANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RESISTANCE EXECISE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; ANIMAL; ENZYMOLOGY; MOUSE; PHYSIOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARDIOTONIC AGENTS; ENZYME ACTIVATION; EXERCISE; HEART FAILURE; HUMANS; MICE; MICE, TRANSGENIC; VENTRICULAR REMODELING;

EID: 63449104127     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080183     Document Type: Review

References (127)

1. Levy, D., Kenchaiah, S., Larson, M. G. et al. (2002) Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347, 1397-1402
2. Nissen, S. E., Tuzcu, E. M., Libby, P. et al. (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 292, 2217-2225
3. Burt, V. L., Cutler, J. A., Higgins, M. et al. (1995) Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 26, 60-69
4. The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327, 685-691
5. Packer, M., Colucci, W. S., Sackner-Bernstein, J. D. et al. (1996) Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation 94, 2793-2799
6. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007
7. Rose, E. A., Gelijns, A. C., Moskowitz, A. J. et al. (2001) Long-term mechanical left ventricular assistance for end-stage heart failure. N. Engl. J. Med. 345, 1435-1443
8. Zannad, F., Briancon, S., Juilliere, Y. et al. (1999) Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine. J. Am. Coll. Cardiol. 33, 734-742
9. Cowie, M. R., Wood, D. A., Coats, A. J. et al. (2000) Survival of patients with a new diagnosis of heart failure: a population based study. Heart 83, 505-510
10. Bleumink, G. S., Knetsch, A. M., Sturkenboom, M. C. et al. (2004) Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur. Heart J. 25, 1614-1619
11. Stewart, S., MacIntyre, K., Capewell, S. and McMurray, J. J. (2003) Heart failure and the aging population: an increasing burden in the 21st century? Heart 89, 49-53
12. Kostis, J. B., Davis, B. R., Cutler, J. et al. (1997) Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA, J. Am. Med. Assoc. 278, 212-216
13. Powell, K. E., Thompson, P. D., Caspersen, C. J. and Kendrick, J. S. (1987) Physical activity and the incidence of coronary heart disease. Annu. Rev. Public Health 8, 253-287
14. Berlin, J. A. and Colditz, G. A. (1990) A meta-analysis of physical activity in the prevention of coronary heart disease. Am. J. Epidemiol. 132, 612-628
15. Haskell,W. L., Lee, I. M., Pate, R. R. et al. (2007) Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 116, 1081-1093
16. Schocken, D. D., Benjamin, E. J., Fonarow, G. C. et al. (2008) Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117, 2544-2565
17. Piepoli, M. F., Scott, A. C., Capucci, A. and Coats, A. J. (2001) Skeletal muscle training in chronic heart failure. Acta Physiol. Scand. 171, 295-303
18. Cleroux, J., Feldman, R. D. and Petrella, R. J. (1999) Lifestyle modifications to prevent and control hypertension. 4. Recommendations on physical exercise training. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. Can. Med. Assoc. J. 160, S21-S28
19. Jennings, G. L. (1995) Mechanisms for reduction of cardiovascular risk by regular exercise. Clin. Exp. Pharmacol. Physiol. 22, 209-211
20. Smart, N. and Marwick, T. H. (2004) Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am. J. Med. 116, 693-706
21. Larsen, A. I., Lindal, S., Aukrust, P., Toft, I., Aarsland, T. and Dickstein, K. (2002) Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. Int. J. Cardiol. 83, 25-32
22. Duscha, B. D., Schulze, P. C., Robbins, J. L. and Forman, D. E. (2008) Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Heart Failure Rev. 13, 21-37
23. McMullen, J. R., Amirahmadi, F., Woodcock, E. A. et al. (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 104, 612-617
24. Eisele, J. C., Schaefer, I. M., Randel Nyengaard, J. et al. (2008) Effect of voluntary exercise on number and volume of cardiomyocytes and their mitochondria in the mouse left ventricle. Basic Res. Cardiol. 103, 12-21
25. Kavazis, A. N., McClung, J. M., Hood, D. A. and Powers, S. K. (2008) Exercise induces a cardiac mitochondrial phenotype that resists apoptotic stimuli. Am. J. Physiol. Heart Circ. Physiol. 294, H928-H935
26. Perrino, C., Naga Prasad, S. V., Mao, L. et al. (2006) Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 116, 1547-1560
27. Schoen, F. J. (2005) The heart. In Robbins and Cotran Pathologic Basis of Disease (Kumar, V., Abbas, A. K. and Fausto, N., eds), pp. 555-618, Elsevier Saunders, Philadelphia
28. Blinderman, C. D., Homel, P., Billings, J. A., Portenoy, R. K. and Tennstedt, S. L. (2008) Symptom distress and quality of life in patients with advanced congestive heart failure. J. Pain Symptom Manag. 35, 594-603
29. Sutton, M. G. and Sharpe, N. (2000) Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101, 2981-2988
30. Mann, D. L. and Bristow, M. R. (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111, 2837-2849
31. Neubauer, S. (2007) The failing heart: an engine out of fuel. N. Engl. J. Med. 356, 1140-1151
32. Ashrafian, H., Frenneaux, M. P. and Opie, L. H. (2007) Metabolic mechanisms in heart failure. Circulation 116, 434-448
33. McMullen, J. R., Sadoshima, J. and Izumo, S. (2005) Physiological versus pathological cardiac hypertrophy. In Molecular Mechanisms of Cardiac Hypertrophy and Failure (Walsh, R. A., ed.), pp. 117-136, Taylor and Francis, London
34. McMullen, J. R. and Jennings, G. L. (2007) Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin. Exp. Pharmacol. Physiol. 34, 255-262
35. Izumo, S., Lompre, A. M., Matsuoka, R. et al. (1987) Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J. Clin. Invest. 79, 970-977
36. Dorn, 2nd, G. W., Robbins, J., Ball, N. and Walsh, R. A. (1994) Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice. Am. J. Physiol. 267, H400-H405
37. Matsui, H., MacLennan, D. H., Alpert, N. R. and Periasamy, M. (1995) Sarcoplasmic reticulum gene expression in pressure overload-induced cardiac hypertrophy in rabbit. Am. J. Physiol. 268, C252-C258
38. Arai, M., Suzuki, T. and Nagai, R. (1996) Sarcoplasmic reticulum genes are upregulated in mild cardiac hypertrophy but downregulated in severe cardiac hypertrophy induced by pressure overload. J. Mol. Cell. Cardiol. 28, 1583-1590
39. van Empel, V. P., Bertrand, A. T., Hofstra, L., Crijns, H. J., Doevendans, P. A. and DeWindt, L. J. (2005) Myocyte apoptosis in heart failure. Cardiovasc. Res. 67, 21-29
40. Adams, J.W., Sakata, Y., Davis, M. G. et al. (1998) Enhanced Gaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc. Natl. Acad. Sci. U.S.A. 95, 10140-10145
41. Sharma, A. K., Dhingra, S., Khaper, N. and Singal, P. K. (2007) Activation of apoptotic processes during transition from hypertrophy to heart failure in guinea pigs. Am. J. Physiol. Heart Circ. Physiol. 293, H1384-H1390
42. Jalil, J. E., Doering, C.W., Janicki, J. S., Pick, R., Shroff, S. G. and Weber, K. T. (1989) Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ. Res. 64, 1041-1050
43. Shioi, T., Kang, P. M., Douglas, P. S. et al. (2000) The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19, 2537-2548
44. McMullen, J. R., Shioi, T., Zhang, L. et al. (2003) Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 100, 12355-12360
45. McMullen, J. R., Shioi, T., Huang, W. Y. et al. (2004) The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110α) pathway. J. Biol. Chem. 279, 4782-4793
46. Heineke, J. and Molkentin, J. D. (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589-600
47. Wang, Y. (2007) Mitogen-activated protein kinases in heart development and diseases. Circulation 116, 1413-1423
48. Wilkins, B. J., Dai, Y. S., Bueno, O. F. et al. (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94, 110-118
49. Janicki, J. S. and Brower, G. L. (2002) The role of myocardial fibrillar collagen in ventricular remodeling and function. J. Card. Failure 8, S319-S325
50. Brower, G. L., Gardner, J. D., Forman, M. F. et al. (2006) The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur. J. Cardiothorac. Surg. 30, 604-610
51. Muller-Brunotte, R., Kahan, T., Lopez, B. et al. (2007) Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J. Hypertens. 25, 1958-1966
52. Rossi, M. A. (1991) Patterns of myocardial fibrosis in idiopathic cardiomyopathies and chronic Chagasic cardiopathy. Can. J. Cardiol. 7, 287-294
53. Brilla, C. G., Zhou, G., Rupp, H., Maisch, B. and Weber, K. T. (1995) Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am. J. Cardiol. 76, 8D-13D
54. Takemura, G. and Fujiwara, H. (2004) Role of apoptosis in remodeling after myocardial infarction. Pharmacol. Ther. 104, 1-16
55. Buja, L. M. and Vela, D. (2008) Cardiomyocyte death and renewal in the normal and diseased heart. Cardiovasc. Pathol. 17, 349-374
56. Hughes, S. E. (2003) Detection of apoptosis using in situ markers for DNA strand breaks in the failing human heart. Fact or epiphenomenon? J. Pathol. 201, 181-186
57. Hayakawa, Y., Chandra, M., Miao, W. et al. (2003) Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Gaq transgenic mice. Circulation 108, 3036-3041
58. Wencker, D., Chandra, M., Nguyen, K. et al. (2003) A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest. 111, 1497-1504
59. Witteles, R. M. and Fowler, M. B. (2008) Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. Coll. Cardiol. 51, 93-102
60. Ritchie, R. H. and Delbridge, L. M. (2006) Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect? Clin. Exp. Pharmacol. Physiol. 33, 159-166
61. Adorisio, R., De Luca, L., Rossi, J. and Gheorghiade, M. (2006) Pharmacological treatment of chronic heart failure. Heart Failure Rev. 11, 109-123
62. Remme, W. J. and Swedberg, K. (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22, 1527-1560
63. Mehta, P. K. and Griendling, K. K. (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292, C82-C97
64. Gourine, A., Bondar, S. I., Spyer, K. M. and Gourine, A. V. (2008) Beneficial effect of the central nervous system beta-adrenoceptor blockade on the failing heart. Circ. Res. 102, 633-636
65. Wang, D. J. and Gottlieb, S. S. (2008) Diuretics: still the mainstay of treatment. Crit. Care Med. 36, S89-S94
66. Boehmer, J. P. (2003) Device therapy for heart failure. Am. J. Cardiol. 91, 53D-59D.
67. Moss, A. J., Hall, W. J., Cannom, D. S. et al. (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl. J. Med. 335, 1933-1940
68. Chen, L. and Hay, J.W. (2004) Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc. Drugs Ther. 18, 161-170
69. Sanders, G. D., Hlatky, M. A. and Owens, D. K. (2005) Cost-effectiveness of implantable cardioverter-defibrillators. N. Engl. J. Med. 353, 1471-1480
70. Rees, K., Taylor, R. S., Singh, S., Coats, A. J. and Ebrahim, S. (2004) Exercise based rehabilitation for heart failure. Cochrane Database Syst. Rev., 3, CD003331
71. Myers, J. (2008) Principles of exercise prescription for patients with chronic heart failure. Heart Failure Rev. 13, 61-68
72. Braith, R. W. and Beck, D. T. (2008) Resistance exercise: training adaptations and developing a safe exercise prescription. Heart Failure Rev. 13, 69-79
73. Hambrecht, R., Niebauer, J., Fiehn, E. et al. (1995) Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J. Am. Coll. Cardiol. 25, 1239-1249
74. European Heart Failure Training Group (1998) Experience from controlled trials of physical training in chronic heart failure. Protocol and patient factors in effectiveness in the improvement in exercise tolerance. Eur. Heart J. 19, 466-475
75. Sturm, B., Quittan, M., Wiesinger, G. F., Stanek, B., Frey, B. and Pacher, R. (1999) Moderate-intensity exercise training with elements of step aerobics in patients with severe chronic heart failure. Arch. Phys. Med. Rehabil. 80, 746-750
76. Tyni-Lenne, R., Dencker, K., Gordon, A., Jansson, E. and Sylven, C. (2001) Comprehensive local muscle training increases aerobic working capacity and quality of life and decreases neurohormonal activation in patients with chronic heart failure. Eur. J. Heart Failure 3, 47-52
77. Roveda, F., Middlekauff, H. R., Rondon, M. U. et al. (2003) The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. J. Am. Coll. Cardiol. 42, 854-860
78. Piepoli, M. F., Davos, C., Francis, D. P. and Coats, A. J. (2004) Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). Br. Med. J. 328, 189
79. Jonsdottir, S., Andersen, K. K., Sigurosson, A. F. and Sigurosson, S. B. (2006) The effect of physical training in chronic heart failure. Eur. J. Heart Failure 8, 97-101
80. Witham, M. D., Daykin, A. R. and McMurdo, M. E. (2008) Pilot study of an exercise intervention suitable for older heart failure patients with left ventricular systolic dysfunction. Eur. J. Cardiovasc. Nurs. 7, 303-306
81. Franciosa, J. A., Park, M. and Levine, T. B. (1981) Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am. J. Cardiol. 47, 33-39
82. Cohn, J. N., Johnson, G. R., Shabetai, R. et al. (1993) Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 87, VI5-V16
83. Sullivan, M. J., Green, H. J. and Cobb, F. R. (1990) Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 81, 518-527
84. Drexler, H., Riede, U., Munzel, T., Konig, H., Funke, E. and Just, H. (1992) Alterations of skeletal muscle in chronic heart failure. Circulation 85, 1751-1759
85. Gosker, H. R., Uszko-Lencer, N. H. M. K., Wouters, E. F. M., van der Vusse, G. J. and Schols, A. M. W. J. (2002) Muscular alterations in chronic obstructive pulmonary disease and chronic heart failure at rest and during exercise. In Clinical Exercise Testing (Weisman, I. M. and Zeballos, R. J., eds), pp. 18-29, Karger, Basel
86. Duscha, B. D., Kraus, W. E., Keteyian, S. J. et al. (1999) Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations. J. Am. Coll. Cardiol. 33, 1956-1963
87. Adams, V., Jiang, H., Yu, J. et al. (1999) Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. 33, 959-965
88. Giannuzzi, P., Temporelli, P. L., Corra, U. and Tavazzi, L. (2003) Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation 108, 554-559
89. Freimann, S., Scheinowitz, M., Yekutieli, D., Feinberg, M. S., Eldar, M. and Kessler-Icekson, G. (2005) Prior exercise training improves the outcome of acute myocardial infarction in the rat. Heart structure, function, and gene expression. J. Am. Coll. Cardiol. 45, 931-938
90. Zhang, K. R., Liu, H. T., Zhang, H. F. et al. (2007) Long-term aerobic exercise protects the heart against ischemia/reperfusion injury via PI3 kinase-dependent and Akt-mediated mechanism. Apoptosis 12, 1579-1588
91. Quindry, J., French, J., Hamilton,K., Lee, Y., Mehta, J. L. and Powers, S. (2005) Exercise training provides cardioprotection against ischemia/ reperfusion induced apoptosis in young and old animals. Exp. Gerontol. 40, 416-425
92. Chicco, A. J., McCune, S. A., Emter, C. A. et al. (2008) Low-intensity exercise training delays heart failure and improves survival in female hypertensive heart failure rats. Hypertension 51, 1096-1102
93. 2+ handling protein expression in heart failure. Physiol. Genomics 29, 246-252
94. Konhilas, J. P., Watson, P. A., Maass, A. et al. (2006) Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ. Res. 98, 540-548
95. Starnes, J.W. and Taylor, R. P. (2007) Exercise-induced cardioprotection: endogenous mechanisms. Med. Sci. Sports Exercise 39, 1537-1543
96. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J. and Waterfield, M. D. (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17, 615-675
97. Oudit, G. Y., Crackower, M. A., Eriksson, U. et al. (2003) Phosphoinositide 3-kinase γ-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108, 2147-2152
98. Crackower, M. A., Oudit, G. Y., Kozieradzki, I. et al. (2002) Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110, 737-749
99. Perrino, C., Schroder, J. N., Lima, B. et al. (2007) Dynamic regulation of phosphoinositide 3-kinase-γ activity and β-adrenergic receptor trafficking in end-stage human heart failure. Circulation 116, 2571-2579
100. Neri Serneri, G. G., Boddi, M., Modesti, P. A. et al. (2001) Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ. Res. 89, 977-982
101. Luo, J., McMullen, J. R., Sobkiw, C. L. et al. (2005) Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol. 25, 9491-9502
102. Tarnavski, O., McMullen, J. R., Schinke, M., Nie, Q., Kong, S. and Izumo, S. (2004) Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol. Genomics 16, 349-360
103. Izumo, S., Nadal-Ginard, B. and Mahdavi, V. (1988) Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc. Natl. Acad. Sci. U.S.A. 85, 339-343
104. Chien, K. R., Zhu, H., Knowlton, K. U. et al. (1993) Transcriptional regulation during cardiac growth and development. Annu. Rev. Physiol. 55, 77-95
105. Su, X., Brower, G., Janicki, J. S., Chen, Y. F., Oparil, S. and Dell'Italia, L. J. (1999) Differential expression of natriuretic peptides and their receptors in volume overload cardiac hypertrophy in the rat. J. Mol. Cell. Cardiol. 31, 1927-1936
106. Sakata, Y., Yamamoto, K., Masuyama, T. et al. (2001) Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J. Hypertens. 19, 1905-1912
107. de Bold, A. J., Ma, K. K., Zhang, Y. et al. (2001) The physiological and pathophysiological modulation of the endocrine function of the heart. Can. J. Physiol. Pharmacol. 79, 705-714
108. Passino, C., Severino, S., Poletti, R. et al. (2006) Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J. Am. Coll. Cardiol. 47, 1835-1839
109. 2+-ATPase expression in the hypertrophic and failing heart. Can. J. Physiol. Pharmacol. 84, 509-521
110. Lu, L., Mei, D. F., Gu, A. G. et al. (2002) Exercise training normalizes altered calcium-handling proteins during development of heart failure. J. Appl. Physiol. 92, 1524-1530
111. Miyamoto, M. I., del Monte, F., Schmidt, U. et al. (2000) Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc. Natl. Acad. Sci. U.S.A. 97, 793-798
112. Kawase, Y., Ly, H. Q., Prunier, F. et al. (2008) Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112-1119
113. Kulik, G., Klippel, A. and Weber, M. J. (1997) Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17, 1595-1606
114. Kuwahara, K., Saito, Y., Kishimoto, I. et al. (2000) Cardiotrophin-1 phosphorylates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J. Mol. Cell. Cardiol. 32, 1385-1394
115. Dhanasekaran, A., Gruenloh, S. K., Buonaccorsi, J. N. et al. (2008) Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am. J. Physiol. Heart Circ. Physiol. 294, H724-H735
116. Zhang, Q. J., Li, Q. X., Zhang, H. F. et al. (2007) Swim training sensitizes myocardial response to insulin: role of Akt-dependent eNOS activation. Cardiovasc. Res. 75, 369-380
117. Chang, L., Chiang, S. H. and Saltiel, A. R. (2004) Insulin signaling and the regulation of glucose transport. Mol. Med. 10, 65-71
118. Belke, D. D., Betuing, S., Tuttle, M. J. et al. (2002) Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 109, 629-639
119. O'Neill, B. T., Kim, J., Wende, A. R. et al. (2007) A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab. 6, 294-306
120. McMurray, J. J. and Pfeffer, M. A. (2005) Heart failure. Lancet 365, 1877-1889
121. Kramer, B. K., Schweda, F. and Riegger, G. A. (1999) Diuretic treatment and diuretic resistance in heart failure. Am. J. Med. 106, 90-96
122. Cully, M., You, H., Levine, A. J. and Mak, T.W. (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192
123. Samuels, Y., Wang, Z., Bardelli, A. et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554
124. Campbell, I. G., Russell, S. E., Choong, D. Y. et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681
125. McMullen, J. R. and Jay, P. Y. (2007) PI3K(p110α) inhibitors as anti-cancer agents: minding the heart. Cell Cycle 6, 910-913
126. Gregorevic, P., Blankinship, M. J., Allen, J. M. et al. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828-834
127. Kerfant, B. G., Rose, R. A., Sun, H. and Backx, P. H. (2006) Phosphoinositide 3-kinase γ regulates cardiac contractility by locally controlling cyclic adenosine monophosphate levels. Trends Cardiovasc. Med. 16, 250-256